Generic Zelboraf Availability
Last updated on Dec 12, 2024.
Zelboraf is a brand name of vemurafenib, approved by the FDA in the following formulation(s):
ZELBORAF (vemurafenib - tablet;oral)
-
Manufacturer: HOFFMANN LA ROCHE
Approval date: August 17, 2011
Strength(s): 240MG [RLD]
Has a generic version of Zelboraf been approved?
No. There is currently no therapeutically equivalent version of Zelboraf available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zelboraf. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 7,504,509
Patent expiration dates:
- October 22, 2026✓✓
- October 22, 2026
-
Patent 7,863,288
Patent expiration dates:
- June 20, 2029✓✓
- June 20, 2029
-
Compounds and methods for kinase modulation, and indications therefor
Patent 8,143,271
Issued: March 27, 2012
Inventor(s): Ibrahim Prabha N. & Artis Dean R. & Bremer Ryan & Zhang Chao & Zhang Jiazhong & Tsai James & Hirth Klaus-Peter & Bollag Gideon & Cho Hanna
Assignee(s): Plexxikon Inc.Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
Patent expiration dates:
- June 21, 2026✓✓
- June 21, 2026
-
Compounds and methods for kinase modulation, and indications therefor
Patent 8,470,818
Issued: June 25, 2013
Inventor(s): Ibrahim Prabha N. & Artis Dean R. & Bremer Ryan & Mamo Shumeye & Zhang Chao & Zhang Jiazhong & Tsai Jianming & Hirth Klaus-Peter & Bollag Gideon & Spevak Wayne & Cho Hanna & Gillette Samuel J. & Shi Shenghua
Assignee(s): Plexxikon Inc.Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
Patent expiration dates:
- August 2, 2026✓
- August 2, 2026✓
- August 2, 2026
-
Process for the manufacture of pharmaceutically active compounds
Patent 8,741,920
Issued: June 3, 2014
Inventor(s): Hildbrand Stefan & Mair Hans-Juergen & Radinov Roumen Nikolaev & Ren Yi & Wright James Anderson
Assignee(s): Hoffmann-La Roche, Inc.The present invention relates to a composition comprising the compound of formula (1),
Patent expiration dates:
- July 27, 2030✓✓
- July 27, 2030
-
Compositions and uses thereof
Patent 9,447,089
Issued: September 20, 2016
Inventor(s): Desai Dipen & Diodone Ralph & Go Zenaida & Ibrahim Prabha N. & Iyer Raman & Mair Hans-Juergen & Sandhu Harpreet K. & Shah Navnit H. & Visor Gary & Wyttenbach Nicole & Lauper Stephan & Pudewell Johannes & Wierschem FrankProvided are solid dispersions, solid molecular complexes, salts and crystalline polymorphs involving propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide.
Patent expiration dates:
- June 6, 2032✓
- June 6, 2032
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- November 6, 2024 - TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION
More about Zelboraf (vemurafenib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (4)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
